- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Access and Rational Use > Financing
- Tous > Medicine Access and Rational Use > Pricing
- Tous > Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Tous > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Mots-clés > affordable prices
- Mots-clés > essential medicines policy
- Mots-clés > innovation and intellectual property
- Mots-clés > The Lancet Commission on Essential Medicines Policies
- Mots-clés > medicines strategy
- Mots-clés > new medicines - prices, costs and affordability
- Mots-clés > patent and exclusivity status
- Mots-clés > prices / pricing policy
- Mots-clés > research and development R&D - costs
- Mots-clés > Trade Related Aspects of the Intellectual Property Rights (TRIPS)
(2016; 2 pages)
The Lancet: http://www.thelancet.com/commissions/essential-medicines
The Lancet Commission on Essential Medicines Policies rightfully addresses the need to guarantee access to essential medicines for all. However, we cannot achieve any real progress without acknowledging that the current patent-based business model and the way we apply international patent rules need to change. The system is broken...
Patent and intellectual property exclusivities are the only cornerstone of the current model. Companies can ask the price they like. This will no longer do. We need to develop alternative business models. And if public money is used for the development of new medicines, agreement upfront is needed about what this public investment will mean for the final price. We believe that companies must provide full transparency regarding the costs of research and development (R&D).
The Dutch Government has recently given a grant to a Dutch initiative called Fair Medicine. This initiative could serve as a potential game changer for the development of new medicines.